发明名称 |
Methods for treatment of attention deficit hyperactivity disorder |
摘要 |
Therapeutic compositions and methods for treatment of attention deficit disorder (ADD) or attention deficit hyperactivity disorder (ADHD) include dosage forms that deliver a therapeutic amount of active drug in a delayed and controlled release formulation. The dosage form can be administered at night and drug release is delayed for from 4 to 6 hours or longer, followed by an ascending release rate. |
申请公布号 |
US9034902(B2) |
申请公布日期 |
2015.05.19 |
申请号 |
US201414577963 |
申请日期 |
2014.12.19 |
申请人 |
Ironshore Pharmaceuticals & Development, Inc. |
发明人 |
Lickrish David;Zhang Feng |
分类号 |
A61K31/4458;A61K9/50;A61K9/54;A61K9/58;A61P25/00;A61P25/26 |
主分类号 |
A61K31/4458 |
代理机构 |
Vinson & Elkins LLP |
代理人 |
Vinson & Elkins LLP |
主权项 |
1. A method of treating a condition in a subject with a disorder or condition responsive to the administration of a methylphenidate, comprising orally administering an effective amount of methylphenidate or a pharmaceutical salt thereof in a formulation comprising a core comprising methylphenidate or a pharmaceutical salt thereof and at least one pharmaceutically acceptable excipient; a sustained release layer enclosing the core and a delayed release layer enclosing the sustained release layer, wherein when the formulation provides an 8 hour lag time during which the formulation releases no more than 10% of the total methylphenidate or a pharmaceutical salt thereof; followed by a sustained release period of 10-12 hours when the composition is placed in 700 ml aqueous solution of 0.1N HCl at pH 1.1, for up to 2 hours; followed by 2-6 hours in sodium phosphate buffer at pH 6.0; followed by 6-20 hours in sodium phosphate buffer, pH 7.2 at 37° C.±0.5° C., measured by the USP Apparatus I. |
地址 |
Camana Bay KY |